News Takeda Pharmaceutical Company Limited London S.E.

Equities

0RN3

JP3463000004

Market Closed - London S.E. Other stock markets 07:28:26 2019-03-26 EDT			5-day change	1st Jan Change
37.59 ^EUR	+6.79%		-.--%	-.--%

04:30am	Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	CI
06-21	Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	10:30pm	CI
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	06-21	MT
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	06-21	DJ
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer	06-21	BU
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	06-21	CI
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older	06-21	AQ
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	06-21	MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	06-21	RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	06-20	MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	06-20	CI
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	06-19	AQ
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat	06-18	AQ
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	06-18	MT
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting	06-18	BU
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	06-18	CI
Takeda's Soticlestat Shows Promising Secondary Outcomes in Phase 3 Studies for Dravet and Lennox-Gastaut Syndromes	06-17	MT
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback	06-17	DJ
Sector Update: Health Care Stocks Decline Premarket Monday	06-17	MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell	06-17	MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	06-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Takeda Pharmaceutical Company Limited London S.E.

Equities

0RN3

JP3463000004

Summary

Filters